View Author
patient cancer trial response vaccine melanoma study group treatment survival interferon phase tumor number cancer vaccines agent combination temozolomide protein development dacarbazine antigen protd disease fficacy observation mage -3 protein point mage -3 center activity vaccination antibody adjuvant stage university product e fficacy trials research toxicity month e ffect therapy e fficacy schedule assay lymph density event production hospital interferon group analysis observation group dendritic recurrence-free survival metastatic death metastasis-free survival dendritic cells pegylated end points immunother safety institute drug administration ifn ␥ progression volume result outcome cytokine end point bene fit randomized development paradigm design population proof-of-principle –mage
5 Most Recent Publications
|
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032)
(Article)
Patel, P. Suciu, S. Becker, J. Conry, R. Thompson, J.A. Hwu, W.-J. Agarwala, S.S. Engelen, K. Keilholz, U. Eggermont, A.M.M. Spatz, A. Mortier, L. Kruit, W.H.J. Robert, C. Schadendorf, D. Trefzer, U. Punt, C.J.A. Dummer, R. Davidson, N. |
2011-07-01
|
|
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
(Article)
Eggermont, A.M.M. Suciu, S. Kusic, Z. Dummer, R. Hauschild, A. Musat, E. Spatz, A. Keilholz, U. Santinami, M. Testori, A. Kruit, W.H.J. Marsden, J. Punt, C.J.A. Salès, F. Gore, M. MacKie, R.M. |
2008-07-14
|
|
Long-term protective effect of mature DC-LAMP
+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma
(Article)
Elliott, B. Scolyer, R.A. Testori, A. Eggermont, A.M.M. MacKie, R.M. Robert, C. Cook, M. Thompson, J.F. Angevin, E. Spatz, A. Suciu, S. Lebecque, S. Rimoldi, D. Gugerli, O. Musat, E. Sharma, R.N. Lienard, D. Keilholz, U. |
2007-07-01
|
|
A clinical development paradigm for cancer vaccines and related biologics
(Article)
Hoos, A. Parmiani, G. Nichol, G. Hege, K. Sznol, M. Loibner, H. Eggermont, A.M.M. Urba, W. Blumenstein, B. Sacks, N. Keilholz, U. |
2007-01-01
|
|
Immunologic Analysis of a Phase I/II Study of Vaccination with MAGE-3 Protein Combined with the AS02B Adjuvant in Patients with MAGE-3-Positive Tumors
(Article)
Vantomme, V. Dantinne, C. Marchand, M.A. Delire, M. Guéguen, M. Amrani, N. Permanne, P. Gheysen, D. Bruck, C. Stoter, G. Britten, C.M. Keilholz, U. Lamers, C.H.J. |
2004-03-01
|
